ClinicalTrials.gg
RecruitingNCT07735637DURGA-6Updated Oct 21, 2026

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

A Phase 3 interventional study of AZD0120 and Cyclophosphamide in Newly Diagnosed Multiple Myeloma (NDMM), sponsored by AstraZeneca. Recruiting at 114 sites in 18 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 21, 2026Now RecruitingFirst sites in China, Japan and Saudi Arabia+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
750
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F in Multiple Myeloma — 7 open to participants now, 7 under way, 3 of them phase 3. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F · Multiple Myeloma.

Planned enrollment
Largest of 11
750 · median 40
Started
2026
with 2 others
Phase 3
3 of 11
3 open now
Registered
11th of 11
by date
Lead sponsor
5 of 11
AstraZeneca

Among the 11 studies testing Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F in Multiple Myeloma, this one has the largest planned enrollment, is one of 3 that started in 2026, is one of 3 in phase 3, and was the 11th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

7 of the 11 studies testing Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to measure the efficacy of AZD0120 compared with ASCT in terms of progression-free survival (PFS) according to the International Myeloma Working Group (IMWG) criteria 2016, and MRD negative complete response (CR) rate at 9 months as assessed by Blinded Independent Central Review (BICR), in participants with TE NDMM.

Study details include:

  • The study duration is estimated to be up to 13 years from the date the first participant is randomised.
  • For participants in Arm A (AZD0120), the total duration of participant follow-up will be 15 years (including a Long Term Follow-up study) after the last participant has received the AZD0120 infusion.
  • The treatment duration will be:- Arm A (AZD0120): lymphodepletion over 3 days, a single-day infusion of AZD0120, followed by a maximum of 2 years lenalidomide monotherapy maintenance treatment.

    • Arm B (ASCT): conditioning therapy over 24 to 48 hours, ASCT, followed by a maximum of 2 years lenalidomide monotherapy maintenance treatment.

Disclosure Statement: This is an open-label, randomised study with 2 treatment arms.

03

Conditions studied

  • Newly Diagnosed Multiple Myeloma (NDMM)

Browse trials for

Keywords

  • Multiple Myeloma
  • NDMM
  • AZD0120
  • cell therapy
  • CAR-T
  • DURGA-6
  • BCMA
  • CD19
  • transplant eligible
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age.
  • Documented diagnosis of NDMM according to IMWG diagnostic criteria.
  • Documented at diagnosis (serum M-protein ≥ 1.0 g/dL, urine M-protein 200 mg/24 hour, or serum Ig FLC 10 mg/dL (100 mg/L) and abnormal serum Ig kappa lambda FLC ratio)
  • Must have completed 4 to 6 cycles of induction therapy with any of the following approved regimens: anti-CD38+VRd, DVTd, DRd or VRd
  • Participant must have at least SD or better per IMWG response criteria (2016) after completion of induction, and prior to randomisation.
  • performance status score of 0 or 1.
  • Eligible for treatment with high-dose melphalan (200 mg/m²) followed by .
  • Adequate organ and bone marrow function.

Exclusion criteria

Exclusion Criteria:

  • Known active, or prior history of CNS involvement or exhibits clinical signs of meningeal involvement of MM.
  • Primary amyloidosis, active plasma cell leukaemia (at diagnosis and/or at time of screening), Waldenstrom macroglobulinemia or POEMS syndrome.
  • Significant neurological or psychiatric condition
  • Significant medical condition that places the participant at an unacceptable risk for treatment-related complications
  • Participants who required the introduction of an additional agent therapy due to inadequate response.
  • Prior T-cell engager therapy directed at any target.
  • Prior CAR-T and/or CAR-NK cell therapy directed at any target for any indications
  • Prior any therapy that is targeted to BCMA and CD19.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
750 participants (estimated)

Study arms

  • Experimental
    Arm A: AZD0120

    AZD0120 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy.

    Biological: AZD0120 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Lenalidomide

  • Active comparator
    Arm B: Autologous Stem Cell Transplant (ASCT)

    ASCT: High-dose melphalan followed by autologous stem cell rescue

    Drug: Melphalan (part of ASCT) · Drug: Lenalidomide

Interventions

  • BiologicalAZD0120

    Arm A: AZD0120 - autologous BCMA/CD19 dual-targeting CAR-T cells. Participants will receive lymphodepletion conditioning (cyclophosphamide and fludarabine) followed by AZD0120 CAR-T cell infusion.

  • Arm A: Cyclophosphamide will be given intravenously as lymphodepletion conditioning.

  • Arm A: Fludarabine will be given intravenously as lymphodepletion conditioning.

  • Arm B - Autologous stem cell transplant: High-dose melphalan will be given over 1-2 days, followed by autologous stem cell rescue.

  • Arm A and Arm B: Lenalidomide maintenance treatment will be started in both Arm A and Arm B after AZD0120 therapy or ASCT, respectively. Lenalidomide maintenance on study will be continued up to 2 years.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as time from randomisation until progression as assessed by Blinded Independent Central Review, or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 13 years.

  2. Minimal Residual Disease (MRD) negative Complete Response Rate (CRR)

    MRD negative CRR is defined as the proportion of participants with a MRD negative status and who have a response of CR or a stringent CR.

    Time frame: Up to approximately 13 years.

Secondary outcomes

  1. Secondary: Overall Survival (OS)

    OS is defined as time from randomisation until date of death due to any cause.

    Time frame: Up to approximately 13 years.

  2. Secondary: Complete Response Rate (CRR)

    CRR (CR or stringent CR rate) is defined as the proportion of participants who achieved CR or better and as assessed by Blinded Independent Central Review.

    Time frame: Up to approximately 13 years.

  3. Secondary: Overall Response Rate (ORR)

    ORR is defined as the proportion of participants with a response (complete, partial or very good partial response) as assessed by Blinded Independent Central Review.

    Time frame: Up to approximately 13 years.

  4. Secondary: Duration of Response (DoR)

    DoR is defined as the time from first response to progression or death

    Time frame: Up to approximately 13 years.

  5. Other secondary: Time to Response (TTR)

    TTR is defined as the time from randomisation to first response

    Time frame: Up to approximately 13 years.

  6. Safety - Adverse Events

    To evaluate safety in terms of the number of participants experiencing an Adverse Event.

    Time frame: Up to approximately 13 years.

07

Study locations

2 of 114 sites recruiting
  • Research Site
    Gilbert, Arizona 85234, United States
    Not yet recruiting
  • Research Site
    Goodyear, Arizona 85338, United States
    Not yet recruiting
  • Research Site
    Phoenix, Arizona 85028, United States
    Not yet recruiting
  • Research Site
    Los Angeles, California 90095, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Orange, California 92868, United States
    Not yet recruiting
  • Research Site
    San Francisco, California 94110, United States
    Not yet recruiting
  • Research Site
    Stanford, California 94305-5824, United States
    Not yet recruiting
  • Research Site
    Denver, Colorado 80218, United States
    Not yet recruiting
  • Research Site
    Jacksonville, Florida 32224, United States
    Not yet recruiting
  • Research Site
    Tampa, Florida 33612, United States
    Not yet recruiting
  • Research Site
    Atlanta, Georgia 30322, United States
    Not yet recruiting
  • Research Site
    Atlanta, Georgia 30342, United States
    Not yet recruiting
  • Research Site
    Newnan, Georgia 30265, United States
    Not yet recruiting
  • Research Site
    Chicago, Illinois 60637, United States
    Not yet recruiting
  • Research Site
    Zion, Illinois 60099, United States
    Not yet recruiting
  • Research Site
    Lexington, Kentucky 40536, United States
    Not yet recruiting
  • Research Site
    Boston, Massachusetts 02118, United States
    Not yet recruiting
  • Research Site
    Boston, Massachusetts 02215, United States
    Not yet recruiting
  • Research Site
    Detroit, Michigan 48201, United States
    Not yet recruiting
  • Research Site
    Rochester, Minnesota 55905, United States
    Not yet recruiting
  • Research Site
    St Louis, Missouri 63110, United States
    Not yet recruiting
  • Research Site
    Great Neck, New York 11021, United States
    Not yet recruiting
  • Research Site
    New York, New York 10021, United States
    Not yet recruiting
  • Research Site
    New York, New York 10029, United States
    Not yet recruiting
  • Research Site
    New York, New York 10032, United States
    Not yet recruiting
  • Research Site
    Rochester, New York 14642, United States
    Not yet recruiting
  • Research Site
    Stony Brook, New York 11794, United States
    Not yet recruiting
  • Research Site
    The Bronx, New York 10467, United States
    Not yet recruiting
  • Research Site
    Chapel Hill, North Carolina 27514, United States
    Not yet recruiting
  • Research Site
    Charlotte, North Carolina 28204, United States
    Not yet recruiting
  • Research Site
    Durham, North Carolina 27705, United States
    Not yet recruiting
  • Research Site
    Winston-Salem, North Carolina 27103, United States
    Not yet recruiting
  • Research Site
    Cleveland, Ohio 44195, United States
    Not yet recruiting
  • Research Site
    Columbus, Ohio 43210, United States
    Not yet recruiting
  • Research Site
    Portland, Oregon 97239, United States
    Not yet recruiting
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
    Not yet recruiting
  • Research Site
    Philadelphia, Pennsylvania 19107, United States
    Not yet recruiting
  • Research Site
    Austin, Texas 78704, United States
    Not yet recruiting
  • Research Site
    Dallas, Texas 75235, United States
    Not yet recruiting
  • Research Site
    Houston, Texas 77030, United States
    Not yet recruiting
  • Research Site
    San Antonio, Texas 78229, United States
    Not yet recruiting
  • Research Site
    Charlottesville, Virginia 22908, United States
    Not yet recruiting
  • Research Site
    Seattle, Washington 98104, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Seattle, Washington 98109, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Madison, Wisconsin 53792, United States
    Not yet recruiting
  • Research Site
    Milwaukee, Wisconsin 53226, United States
    Not yet recruiting
  • Research Site
    Brisbane, 4102, Australia
    Not yet recruiting
  • Research Site
    Camperdown, 2050, Australia
    Not yet recruiting
  • Research Site
    Darlinghurst, 2010, Australia
    Not yet recruiting
  • Research Site
    East Melbourne, 3002, Australia
    Not yet recruiting
  • Research Site
    Fitzroy, 3065, Australia
    Recruiting
  • Research Site
    Melbourne, 3004, Australia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Nedlands, 6009, Australia
    Not yet recruiting
  • Research Site
    Westmead, 2145, Australia
    Not yet recruiting
  • Research Site
    Salvador, 41253-190, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 01509-900, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 05652-900, Brazil
    Not yet recruiting
  • Research Site
    Calgary, Alberta T2N 5G2, Canada
    Not yet recruiting
  • Research Site
    Halifax, Nova Scotia B3H 2Y9, Canada
    Not yet recruiting
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
    Not yet recruiting
  • Research Site
    Sherbrooke, Quebec J1G 2K7, Canada
    Not yet recruiting
  • Research Site
    Beijing, 100044, China
    Not yet recruiting
  • Research Site
    Shanghai, 201210, China
    Not yet recruiting
  • Research Site
    Aarhus, 8200, Denmark
    Not yet recruiting
  • Research Site
    København Ø, 2100, Denmark
    Not yet recruiting
  • Research Site
    Odense, 5464, Denmark
    Not yet recruiting
  • Research Site
    Lille, 59037, France
    Not yet recruiting
  • Research Site
    Nantes, 44093, France
    Not yet recruiting
  • Research Site
    Paris, 75012, France
    Not yet recruiting
  • Research Site
    Paris, 75475, France
    Not yet recruiting
  • Research Site
    Toulouse, 31059, France
    Not yet recruiting
  • Research Site
    Berlin, 10117, Germany
    Not yet recruiting
  • Research Site
    Dresden, 01307, Germany
    Not yet recruiting
  • Research Site
    Essen, 45122, Germany
    Not yet recruiting
  • Research Site
    Freiburg im Breisgau, 79106, Germany
    Not yet recruiting
  • Research Site
    Hamburg, 20246, Germany
    Not yet recruiting
  • Research Site
    Leipzig, 04103, Germany
    Not yet recruiting
  • Research Site
    München, 81675, Germany
    Not yet recruiting
  • Research Site
    Oldenburg, 26133, Germany
    Not yet recruiting
  • Research Site
    Bologna, 40138, Italy
    Not yet recruiting
  • Research Site
    Milan, 20133, Italy
    Not yet recruiting
  • Research Site
    Milan, 20141, Italy
    Not yet recruiting
  • Research Site
    Rome, 00168, Italy
    Not yet recruiting
  • Research Site
    Rozzano, 20089, Italy
    Not yet recruiting
  • Research Site
    Torino, 10100, Italy
    Not yet recruiting
  • Research Site
    Nagoya, 467-8602, Japan
    Not yet recruiting
  • Research Site
    Oslo, 0450, Norway
    Not yet recruiting
  • Research Site
    Gdansk, 80-214, Poland
    Not yet recruiting
  • Research Site
    Gliwice, 44-100, Poland
    Not yet recruiting
  • Research Site
    Kielce, 25-734, Poland
    Not yet recruiting
  • Research Site
    Krakow, 30-688, Poland
    Not yet recruiting
  • Research Site
    Lublin, 20-090, Poland
    Not yet recruiting
  • Research Site
    Wroclaw, 50-556, Poland
    Not yet recruiting
  • Research Site
    Riyadh, 11211, Saudi Arabia
    Not yet recruiting
  • Research Site
    Riyadh, 11426, Saudi Arabia
    Not yet recruiting
  • Research Site
    Singapore, 119074, Singapore
    Not yet recruiting
  • Research Site
    Singapore, 169608, Singapore
    Not yet recruiting
  • Research Site
    Seoul, 03080, South Korea
    Not yet recruiting
  • Research Site
    Seoul, 06351, South Korea
    Not yet recruiting
  • Research Site
    Seoul, 06591, South Korea
    Not yet recruiting

Showing the first 100 of 114 sites across 18 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Nov 2028, 25 months after the start.

Of 108 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 25 months is below that.

Counting every sponsor, half of 180 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Aug 2026 → Sep 2026 and primary completion Oct 2028 → Nov 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2026
First posted
Jul 30, 2026
StartActual
Sep 24, 2026was Aug 2026
Primary completionEst.
Nov 2, 2028was Oct 2028
CompletionEst.
Nov 17, 2039
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 21, 2026
Sites
49 sites added — first sites in China, Japan and Saudi Arabia. 57 sites changed recruiting status (53 now not yet recruiting, 2 now withdrawn, …)
Show 57 sites
  • Research Site · Tampa, United Statesno status→Not yet recruiting
  • Research Site · Atlanta, United Statesno status→Not yet recruiting
  • Research Site · Chicago, United Statesno status→Not yet recruiting
  • Research Site · Detroit, United Statesno status→Not yet recruiting
  • Research Site · Rochester, United Statesno status→Not yet recruiting
  • Research Site · Cleveland, United Statesno status→Not yet recruiting
  • Research Site · San Antonio, United Statesno status→Not yet recruiting
  • Research Site · Seattle, United Statesno status→Withdrawn
  • Research Site · Milwaukee, United Statesno status→Not yet recruiting
  • Research Site · Brisbane, Australiano status→Not yet recruiting
  • Research Site · Camperdown, Australiano status→Not yet recruiting
  • Research Site · Darlinghurst, Australiano status→Not yet recruiting
  • Research Site · Fitzroy, Australiano status→Recruiting
  • Research Site · Melbourne, Australiano status→Withdrawn
  • Research Site · Nedlands, Australiano status→Not yet recruiting
  • Research Site · Salvador, Brazilno status→Not yet recruiting
  • Research Site · São Paulo, Brazilno status→Not yet recruiting
  • Research Site · Calgary, Canadano status→Not yet recruiting
  • Research Site · Aarhus, Denmarkno status→Not yet recruiting
  • Research Site · København Ø, Denmarkno status→Not yet recruiting
  • Research Site · Odense, Denmarkno status→Not yet recruiting
  • Research Site · Lille, Franceno status→Not yet recruiting
  • Research Site · Nantes, Franceno status→Not yet recruiting
  • Research Site · Paris, Franceno status→Not yet recruiting
  • Research Site · Toulouse, Franceno status→Not yet recruiting
  • Research Site · Berlin, Germanyno status→Not yet recruiting
  • Research Site · Dresden, Germanyno status→Not yet recruiting
  • Research Site · Essen, Germanyno status→Not yet recruiting
  • Research Site · Freiburg im Breisgau, Germanyno status→Not yet recruiting
  • Research Site · Hamburg, Germanyno status→Not yet recruiting
  • …and 27 more on the registry record
Show 49 added (36 United States, 3 Canada, 3 Taiwan, 2 Australia, 2 China, 2 Saudi Arabia, 1 Japan)
  • Research Site · Gilbert, United States
  • Research Site · Goodyear, United States
  • Research Site · Phoenix, United States
  • Research Site · Los Angeles, United States
  • Research Site · Orange, United States
  • Research Site · San Francisco, United States
  • Research Site · Stanford, United States
  • Research Site · Denver, United States
  • Research Site · Jacksonville, United States
  • Research Site · Newnan, United States
  • Research Site · Zion, United States
  • Research Site · Lexington, United States
  • Research Site · Boston, United States
  • Research Site · Boston, United States
  • Research Site · St Louis, United States
  • Research Site · Great Neck, United States
  • Research Site · New York, United States
  • Research Site · New York, United States
  • Research Site · New York, United States
  • Research Site · Rochester, United States
  • Research Site · Stony Brook, United States
  • Research Site · The Bronx, United States
  • Research Site · Chapel Hill, United States
  • Research Site · Charlotte, United States
  • Research Site · Durham, United States
  • Research Site · Winston-Salem, United States
  • Research Site · Columbus, United States
  • Research Site · Portland, United States
  • Research Site · Philadelphia, United States
  • Research Site · Philadelphia, United States
  • …and 19 more on the registry record
Oct 21, 2026
Start date
Aug 25, 2026→Sep 24, 2026 (actual)
Oct 21, 2026
Primary completion
Oct 11, 2028→Nov 2, 2028
Oct 21, 2026
Study completion
Nov 9, 2039→Nov 17, 2039
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Not yet recruiting→Recruiting
    49 sites added — first sites in China, Japan and Saudi Arabia. 65 sites changed recruiting status (61 now not yet recruiting, 2 now withdrawn, …)
    Show 65 sites
    • Research Site · Tampa, United Statesno status→Not yet recruiting
    • Research Site · Atlanta, United Statesno status→Not yet recruiting
    • Research Site · Atlanta, United Statesno status→Not yet recruiting
    • Research Site · Chicago, United Statesno status→Not yet recruiting
    • Research Site · Detroit, United Statesno status→Not yet recruiting
    • Research Site · Rochester, United Statesno status→Not yet recruiting
    • Research Site · Cleveland, United Statesno status→Not yet recruiting
    • Research Site · San Antonio, United Statesno status→Not yet recruiting
    • Research Site · Seattle, United Statesno status→Withdrawn
    • Research Site · Milwaukee, United Statesno status→Not yet recruiting
    • Research Site · Brisbane, Australiano status→Not yet recruiting
    • Research Site · Camperdown, Australiano status→Not yet recruiting
    • Research Site · Darlinghurst, Australiano status→Not yet recruiting
    • Research Site · Fitzroy, Australiano status→Recruiting
    • Research Site · Melbourne, Australiano status→Withdrawn
    • Research Site · Nedlands, Australiano status→Not yet recruiting
    • Research Site · Salvador, Brazilno status→Not yet recruiting
    • Research Site · São Paulo, Brazilno status→Not yet recruiting
    • Research Site · São Paulo, Brazilno status→Not yet recruiting
    • Research Site · Calgary, Canadano status→Not yet recruiting
    • Research Site · Aarhus, Denmarkno status→Not yet recruiting
    • Research Site · København Ø, Denmarkno status→Not yet recruiting
    • Research Site · Odense, Denmarkno status→Not yet recruiting
    • Research Site · Lille, Franceno status→Not yet recruiting
    • Research Site · Nantes, Franceno status→Not yet recruiting
    • Research Site · Paris, Franceno status→Not yet recruiting
    • Research Site · Paris, Franceno status→Not yet recruiting
    • Research Site · Toulouse, Franceno status→Not yet recruiting
    • Research Site · Berlin, Germanyno status→Not yet recruiting
    • Research Site · Dresden, Germanyno status→Not yet recruiting
    • …and 35 more on the registry record
    Show 49 added (36 United States, 3 Canada, 3 Taiwan, 2 Australia, 2 China, 2 Saudi Arabia, 1 Japan)
    • Research Site · Gilbert, United States
    • Research Site · Goodyear, United States
    • Research Site · Phoenix, United States
    • Research Site · Los Angeles, United States
    • Research Site · Orange, United States
    • Research Site · San Francisco, United States
    • Research Site · Stanford, United States
    • Research Site · Denver, United States
    • Research Site · Jacksonville, United States
    • Research Site · Newnan, United States
    • Research Site · Zion, United States
    • Research Site · Lexington, United States
    • Research Site · Boston, United States
    • Research Site · Boston, United States
    • Research Site · St Louis, United States
    • Research Site · Great Neck, United States
    • Research Site · New York, United States
    • Research Site · New York, United States
    • Research Site · New York, United States
    • Research Site · Rochester, United States
    • Research Site · Stony Brook, United States
    • Research Site · The Bronx, United States
    • Research Site · Chapel Hill, United States
    • Research Site · Charlotte, United States
    • Research Site · Durham, United States
    • Research Site · Winston-Salem, United States
    • Research Site · Columbus, United States
    • Research Site · Portland, United States
    • Research Site · Philadelphia, United States
    • Research Site · Philadelphia, United States
    • …and 19 more on the registry record
    Start date Aug 25, 2026→Sep 24, 2026 (now actual)
    Primary completion Oct 11, 2028→Nov 2, 2028
    Study completion Nov 9, 2039→Nov 17, 2039
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07735637
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 30, 2026
Start date
Sep 24, 2026
Primary completion
Nov 2, 2028 (estimated)
Completion
Nov 17, 2039 (estimated)
Last update
Oct 21, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F

Start the discussion